SCHEMBL3278461

SCHEMBL3278461

CNC(=O)c1cccc(-c2ccn3c(-c4ocnc4C)nnc3c2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 1/20 0.40
PIK3CG P48736 1/20 0.40
MAPK14 Q16539 1/20 0.39
FGFR1 P11362 1/20 0.39
FGFR3 P22607 1/20 0.39
IMPDH2 P12268 1/20 0.39
FYN P06241 4/20 0.39
PIP5K1C O60331 1/20 0.39
PIK3CA P42336 1/20 0.39
NR4A2 P43354 1/20 0.38
KDM5A P29375 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
KDM5B Q9UGL1 1/20 0.38
ADRA2A P08913 1/20 0.38
ADRA1A P35348 1/20 0.38
MAPK13 O15264 1/20 0.37
KDR P35968 1/20 0.37
POLQ O75417 1/20 0.36
MAP4K4 O95819 1/20 0.36
GRM5 P41594 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3277409 0.79 MAPK13 (0.52) CDK8PIK3CGMAPK14NR4A2ADRA2A
SCHEMBL3277809 0.76 MAPK14 (0.42) CDK8PIK3CGMAPK14FGFR1FGFR3
SCHEMBL3278458 0.75 IMPDH2 (0.36) MAPK14FGFR3IMPDH2MAPK13KDR
SCHEMBL3279744 0.75 PDK2 (0.46) MAPK14ADRA2AADRA1AMAPK13KDR
SCHEMBL380491 0.73 MAPK13 (0.46) MAPK14MAPK13
SCHEMBL3025015 0.71 FGFR3 (0.49) CDK8PIK3CGFGFR1FGFR3FYN
SCHEMBL379802 0.71 MAPK13 (0.70) MAPK14MAPK13
SCHEMBL3025051 0.69 CDK8 (0.49) CDK8PIK3CGFGFR1FGFR3FYN
SCHEMBL13702375 0.69 HDAC8 (0.68) CDK8PIK3CGFYNPIP5K1CPIK3CA
SCHEMBL13336647 0.67 KDR (0.65) FGFR1FGFR3FYNKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7700593-B2 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2010-04-20 US disclosed
US-20080161303-A1 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161303-A1 Imidazo- and triazolo-pyridine compounds and methods of use thereof MAPK1, MAP3K1, MAP3K7 CDK8 177/4885PIK3CG 722/4885MAPK14 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.